X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN AJANTA PHARMA/
LUPIN
 
P/E (TTM) x 23.6 41.4 57.0% View Chart
P/BV x 4.5 2.5 176.4% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 AJANTA PHARMA   LUPIN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
LUPIN
Mar-18
AJANTA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,8181,465 124.1%   
Low Rs1,106727 152.1%   
Sales per share (Unadj.) Rs239.5349.6 68.5%  
Earnings per share (Unadj.) Rs52.85.6 949.9%  
Cash flow per share (Unadj.) Rs59.529.6 201.2%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs230.0300.3 76.6%  
Shares outstanding (eoy) m88.77452.08 19.6%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.13.1 194.7%   
Avg P/E ratio x27.7197.2 14.0%  
P/CF ratio (eoy) x24.637.1 66.3%  
Price / Book Value ratio x6.43.6 174.2%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m129,782495,502 26.2%   
No. of employees `0006.817.0 39.9%   
Total wages/salary Rs m3,76528,647 13.1%   
Avg. sales/employee Rs Th3,128.49,273.6 33.7%   
Avg. wages/employee Rs Th554.01,681.0 33.0%   
Avg. net profit/employee Rs Th689.7147.4 467.8%   
INCOME DATA
Net Sales Rs m21,258158,042 13.5%  
Other income Rs m2421,504 16.1%   
Total revenues Rs m21,499159,545 13.5%   
Gross profit Rs m6,58431,475 20.9%  
Depreciation Rs m59610,859 5.5%   
Interest Rs m42,044 0.2%   
Profit before tax Rs m6,22620,076 31.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,5392,885 53.4%   
Profit after tax Rs m4,6862,513 186.5%  
Gross profit margin %31.019.9 155.5%  
Effective tax rate %24.714.4 172.1%   
Net profit margin %22.01.6 1,386.7%  
BALANCE SHEET DATA
Current assets Rs m12,236122,095 10.0%   
Current liabilities Rs m3,46150,956 6.8%   
Net working cap to sales %41.345.0 91.7%  
Current ratio x3.52.4 147.6%  
Inventory Days Days6085 71.2%  
Debtors Days Days84120 70.5%  
Net fixed assets Rs m11,140129,876 8.6%   
Share capital Rs m177904 19.6%   
"Free" reserves Rs m20,237134,866 15.0%   
Net worth Rs m20,414135,771 15.0%   
Long term debt Rs m1064,245 0.0%   
Total assets Rs m24,486263,054 9.3%  
Interest coverage x1,519.410.8 14,036.8%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.90.6 144.5%   
Return on assets %19.21.7 1,106.0%  
Return on equity %23.01.9 1,240.5%  
Return on capital %30.53.7 819.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66753,141 22.0%   
Fx outflow Rs m1,61619,335 8.4%   
Net fx Rs m10,05233,807 29.7%   
CASH FLOW
From Operations Rs m2,85417,512 16.3%  
From Investments Rs m-2,604-14,073 18.5%  
From Financial Activity Rs m-2-14,921 0.0%  
Net Cashflow Rs m248-11,482 -2.2%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   BIOCON   WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS